Combination Therapy with Paromomycin-Associated Stearylamine-Bearing Liposomes Cures Experimental Visceral Leishmaniasis through Th1-Biased Immunomodulation

Complete Cure of Experimental Visceral Leishmaniasis with Amphotericin B in Stearylamine-Bearing Cationic Liposomes Involves Down-Regulation of IL-10 and Favorable T Cell Responses

(2014) A. Banerjee et al.   JOURNAL OF IMMUNOLOGY

Dichotomy of the T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis; absence or scarcity of Th1 activity is associated with severe infections

(2010) A. GAAFAR et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Topical delivery andin vivoantileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis

(2010) Guilherme Carneiro et al.   JOURNAL OF LIPOSOME RESEARCH

Effect of Topical Liposomes Containing Paromomycin Sulfate in the Course of Leishmania major Infection in Susceptible BALB/c Mice

(2009) M. R. Jaafari et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The p110  Isoform of Phosphatidylinositol 3-Kinase Controls Susceptibility to Leishmania major by Regulating Expansion and Tissue Homing of Regulatory T Cells

(2009) D. Liu et al.   JOURNAL OF IMMUNOLOGY

Paromomycin in the treatment of leishmaniasis

(2008) Shyam Sundar et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS